Market News & Trends
Croda Enters Contract With Pfizer for Innovative Delivery System for COVID-19 Vaccine
Croda International Plc recently announced it has entered into an agreement with Pfizer Inc. to supply novel excipients used in the manufacture of a COVID-19….
Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID its Single-Dose Intranasal Vaccine Candidate for COVID-19
Altimmune, Inc. recently announced that it entered into an agreement with Lonza for the manufacturing of AdCOVID, Altimmune’s next-generation, single-dose intranasal vaccine candidate for COVID-19.…
4D Pharma Presents New Data From Two MRx0518 Clinical Trials
4D pharma plc recently announced new positive clinical data from two clinical trials of MRx0518, its lead immuno-oncology single strain Live Biotherapeutic candidate. The data was…
Axovant Gene Therapies Announces FDA Clearance of IND for Gene Therapy
Axovant Gene Therapies Ltd. recently announced the US FDA has lifted its clinical hold and cleared the Investigational New Drug (IND) Application to initiate a registrational study of….
Mateon Therapeutics & Windlas Biotech Enter Commercialization Agreement for Covid-19 Drug
Mateon Therapeutics recently announced an agreement with Windlas Biotech Pvt. Ltd. of India (Windlas) to commercialize ARTIVeda, Mateon’s lead ethnobiology….
Dolomite Microfluidics & MilliporeSigma Collaborate to Release Off-the-Shelf Microfluidic Device Kits for the Fabrication of PLGA Particles
Dolomite Microfluidics and MilliporeSigma have partnered to create a range of off-the-shelf NanoFabTx™ microfluidic device kits for the production of….
Pfizer & BioNTech Reach Agreement to Supply the EU With 200 Million Doses of COVID-19 Vaccine
Pfizer and BioNTech SE recently announced they have reached an agreement with the European Commission to supply 200 million doses of their investigational….
Novo Nordisk to Acquire Emisphere Technologies for $1.35 Billion
Emisphere Technologies, Inc. recently announced it has entered into a definitive agreement with Novo Nordisk, whereby Novo Nordisk will acquire Emisphere, on a cash-free, debt-free basis, for….
CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabetes
CymaBay Therapeutics, Inc. recently announced it will provide its proprietary investigational GPR119 agonist, MBX-2982, and will assist in regulatory filings for….
eGenesis Announces Research Collaboration With Leading Academic Medical Center
eGenesis recently announced the initiation of a research collaboration with Duke University School of Medicine. The collaboration will encompass evaluation of gene-edited pancreatic islet….
Calithera Biosciences Announces Expansion of Ongoing Clinical Trial
Calithera Biosciences, Inc. recently announced the expansion of the company’s ongoing clinical trial evaluating telaglenastat in combination with Pfizer’s CDK 4/6 inhibitor palbociclib….
European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application
Biogen and Eisai, Co., Ltd. recently announced that the European Medicines Agency (EMA) has confirmed it has accepted for review, following a standard timetable, the…
Taysha Gene Therapies Bolsters Manufacturing Capacity Through Partnership
Taysha Gene Therapies Inc. and Catalent recently announced a partnership to support the development and manufacturing of Taysha’s gene therapies at Catalent’s Maryland-based gene therapy…
Rubius Therapeutics Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial
Rubius Therapeutics, Inc. recently announced that the first patient with acute myeloid leukemia (AML) has been dosed in its ongoing Phase 1/2 clinical trial of…
Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation
Orchard Therapeutics recently announced the presentation of new clinical data at the upcoming 62nd American Society of Hematology (ASH) Annual Meeting to be held virtually…
Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 Trials for the Treatment of Parkinson’s Disease
Cerevel Therapeutics recently announced that the first participants have been dosed in all three of the clinical trials in their Phase 3 program evaluating tavapadon…
Aerogen Collaborates on Development of More Than 15 Potential COVID-19 Inhaled Therapies
Aerogen recently announced details of a broad collaborative effort to support pharmaceutical companies from around the world as they work to develop COVID-19 vaccines and…
APPLY NOW ! - A Novel Approach for Incentivizing Drug Delivery Innovation
One of the most critical early steps in the development of novel drug delivery systems is to demonstrate convincing proof-of-concept. The dilemma is that while pharma companies can be interested in….
Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company
Vedere Bio, Inc. recently announced it has been acquired by Novartis. Shareholders in Vedere Bio received $150 million upfront and….
Nemera to Acquire Copernicus to Boost Parenteral Product Portfolio & Small Series Capabilities
Nemera recently announced it has entered into an agreement to acquire Copernicus, which specializes in the development and manufacturing of injection devices…
